Melinda Fuqua, NP
Family · Terre Haute, INNPI 1215223151
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Phathom Pharmaceuticals, Inc. at 47.5% of the total. Among family clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 391 payments — averaging $47.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$9K
- AbbVie$3K
- Johnson & Johnson$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$775
- Takeda Pharmaceuticals U.S.A., Inc.$691
- Sanofi$474
- plus $3K from 27 others
What the payments were for
- Speaking & faculty fees$6,80036%
- Travel & lodging$9395%
- Food & beverage$10,93758%
- Education$690%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 31 | $8,898 |
| AbbVie | 120 | $3,250 |
| Johnson & Johnson | 43 | $1,774 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 43 | $775 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $691 |
| Sanofi | 9 | $474 |
| Gilead | 11 | $415 |
| Janssen Scientific Affairs, LLC | 4 | $347 |
| QOL Medical, LLC | 11 | $240 |
| Lilly USA, LLC | 10 | $199 |
| Pfizer | 12 | $198 |
| Regeneron Healthcare Solutions, Inc. | 10 | $193 |
| Ironwood Pharmaceuticals, Inc | 9 | $165 |
| Ardelyx, Inc. | 6 | $157 |
| Aimmune Therapeutics, Inc. | 5 | $134 |
| E.r. Squibb & Sons, L.L.C. | 1 | $119 |
| Intercept Pharmaceuticals, Inc. | 5 | $84 |
| Daiichi Sankyo Inc. | 3 | $70 |
| Organon | 3 | $66 |
| Braintree Laboratories, Inc. | 3 | $58 |
| Boston Scientific | 2 | $51 |
| Madrigal Pharmaceuticals | 2 | $47 |
| Dynavax Technologies Corporation | 3 | $47 |
| Bristol Myers Squibb | 3 | $44 |
| Merck | 3 | $42 |
| Nestle Healthcare Nutrition Inc. | 2 | $42 |
| Amgen | 2 | $35 |
| Exact Sciences | 2 | $35 |
| Ipsen Biopharmaceuticals, Inc | 2 | $32 |
| Digestive Care, Inc. | 1 | $18 |
| Medtronic | 1 | $15 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Echosens North America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,745 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 70 | $554,340 |
| Skyrizi On-BodyRisankizumab-Rzaa | 23 | $456,583 |
| StelaraUstekinumab | 16 | $441,533 |
| XifaxanRifaximin | 56 | $185,461 |
| LinzessLinaclotide | 154 | $150,536 |
| CreonLipase/Protease/Amylase | 22 | $82,085 |
| IbsrelaTenapanor Hcl | 23 | $61,255 |
| ZenpepLipase/Protease/Amylase | 11 | $44,331 |
| VoqueznaVonoprazan Fumarate | 44 | $29,608 |
| MotegrityPrucalopride Succinate | 18 | $25,449 |
| Dexlansoprazole DrDexlansoprazole | 71 | $24,230 |
| Mesalamine | 31 | $10,496 |
| TrulancePlecanatide | 14 | $7,862 |
| Pantoprazole Sodium | 594 | $7,421 |
| Mesalamine ErMesalamine | 19 | $7,405 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,774 | $441,53316 claims |
| AbbVieLinzess, Creon | $3,250 | $232,621176 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $775 | $193,32470 claims |
| Ardelyx, Inc.Ibsrela | $157 | $61,25523 claims |
| Aimmune Therapeutics, Inc.Zenpep | $134 | $44,33111 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $8,898 | $29,60844 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $691 | $25,44918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.
Other family in Terre Haute
- Stephanie ArnoldTerre Haute$52K
- Daxton DuncanTerre Haute$31K
- Tamara GormanTerre Haute$16K
- Kathy BannonTerre Haute$15K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.